Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.47 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.46 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.42 |
| ▸ | KAT2B | Q92831 | 2/20 | 0.42 |
| ▸ | ACHE | P22303 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL404758 | 0.81 | VCAM1 (0.64) | TSHRCYP3A4GPR35VCAM1KAT2B | |
| SCHEMBL9793498 | 0.79 | PTPN11 (0.49) | TSHRCYP3A4PTPN11VCAM1KAT2B | |
| SCHEMBL5499188 | 0.79 | TDP1 (0.55) | TSHRPTPN11GPR35VCAM1HSD17B10 | |
| SCHEMBL13982692 | 0.78 | VCAM1 (0.69) | TSHRPTPN11VCAM1ALDH1A1LMNA | |
| SCHEMBL17875621 | 0.78 | ALDH1A1 (0.58) | TSHRCYP3A4PTPN11VCAM1HSD17B10 | |
| SCHEMBL28019069 | 0.78 | PTPN11 (0.47) | TSHRCYP3A4PTPN11GPR35VCAM1 | |
| SCHEMBL709465 | 0.77 | MAPK1 (0.46) | TSHRCYP3A4PTPN11GPR35VCAM1 | |
| SCHEMBL9129347 | 0.77 | ALDH1A1 (0.51) | CYP3A4PTPN11KDM4EALDH1A1MAPT | |
| SCHEMBL15218940 | 0.76 | TSHR (0.53) | TSHRCYP3A4GPR35VCAM1KAT2B | |
| SCHEMBL294724 | 0.76 | TSHR (1.00) | TSHRCYP3A4GPR35KAT2BACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8946478-B2 | Benzamide derivative with anticancer activity and preparation method and use thereof | ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) | 2015-02-03 | — | — | US | disclosed |
| US-20130225810-A1 | BENZAMIDE DERIVATIVE WITH ANTICANCER ACTIVITY AND PREPARATION METHOD AND USE THEREOF | ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) | 2013-08-29 | — | — | US | disclosed |
| US-7560462-B2 | Compounds useful for inhibiting CHK1 | ICOS CORPORATION (US) | 2009-07-14 | — | — | US | disclosed |
| US-20080214573-A1 | Compounds Useful for Inhibiting Chk1 | ICOS CORPORATION (US) | 2008-09-04 | — | — | US | disclosed |
| CN-101010316-A | Compounds useful for inhibiting CHK1 | ICOS CORP (US) | 2007-08-01 | — | — | CN | disclosed |
| EP-1768977-A2 | COMPOUNDS USEFUL FOR INHIBITING CHK1 | ICOS Corporation (US) | 2007-04-04 | — | — | EP | disclosed |
| WO-2006014359-A2 | COMPOUNDS USEFUL FOR INHIBITING CHK1 | ICOS CORPORATION (US) | 2006-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225810-A1 | BENZAMIDE DERIVATIVE WITH ANTICANCER ACTIVITY AND PREPARATION METHOD AND USE THEREOF | HDAC5, TMBIM6, HDAC6 | TSHR 4200/4885CYP3A4 350/4885PTPN11 4703/4885 |
| US-20080214573-A1 | Compounds Useful for Inhibiting Chk1 | ORC3, MCM3, CHEK1 | TSHR 1478/4885CYP3A4 3598/4885PTPN11 3455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.